Depixus, a pioneering company in the field of intereactomics, has been awarded the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at their annual International Conference and Exhibition in Boston, MA. This recognition comes after the unveiling of their groundbreaking MAGNA One™ instrument at the conference.
The Ignite Award is presented to companies that are revolutionizing the life sciences through innovative technologies. Depixus was one of just 16 companies selected to participate in the SLAS2024 Innovation AveNEW program, which is a dedicated area for start-ups and emerging companies within the conference. From this group of 16 companies, eight were chosen as finalists for the award.
MAGNA One is based on magnetic force spectroscopy, enabling high-throughput analysis of dynamic biomolecular interactions. This technology is unique in that it allows for real-time measurements from thousands of individual molecules simultaneously, making it particularly valuable for exploring challenging targets such as RNA and protein-protein interactions. These insights accelerate the development of novel therapeutics and provide valuable insights into disease mechanisms.
Depixus CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that this recognition coincides with the launch of their technology access program and commercial rollout of MAGNA One, marking a significant moment for Depixus as they continue to lead innovation in intereactomics.
For more information about Depixus or their MAGNA One instrument, visit depixus.com or contact Steve Klose at firstname.lastname@example.org.